D. Boral Capital Reaffirms Buy Rating for Checkpoint Therapeutics (NASDAQ:CKPT)

D. Boral Capital restated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has a $4.80 price objective on the stock.

Other equities analysts have also issued research reports about the company. Lake Street Capital reissued a “hold” rating and set a $4.10 price objective (down previously from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. HC Wainwright reissued a “neutral” rating and set a $4.10 price target on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th.

Checkpoint Therapeutics Stock Performance

NASDAQ:CKPT opened at $4.04 on Monday. The company has a market cap of $197.29 million, a P/E ratio of -2.20 and a beta of 1.41. Checkpoint Therapeutics has a twelve month low of $1.38 and a twelve month high of $4.50. The company’s 50-day moving average price is $3.38 and its 200-day moving average price is $3.30.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its earnings results on Friday, March 28th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.47). The business had revenue of $0.04 million for the quarter. On average, analysts expect that Checkpoint Therapeutics will post -0.94 earnings per share for the current year.

Insider Activity

In other Checkpoint Therapeutics news, CEO James F. Oliviero III sold 9,233 shares of the company’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $3.41, for a total transaction of $31,484.53. Following the transaction, the chief executive officer now directly owns 3,785,350 shares in the company, valued at $12,908,043.50. This represents a 0.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO William Garrett Gray sold 74,110 shares of Checkpoint Therapeutics stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $3.67, for a total value of $271,983.70. Following the completion of the sale, the chief financial officer now directly owns 1,458,644 shares of the company’s stock, valued at $5,353,223.48. The trade was a 4.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 93,674 shares of company stock valued at $336,011. 2.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Checkpoint Therapeutics

Several hedge funds have recently bought and sold shares of CKPT. SBI Securities Co. Ltd. purchased a new stake in Checkpoint Therapeutics during the 4th quarter worth approximately $32,000. State Street Corp raised its stake in shares of Checkpoint Therapeutics by 32.2% in the third quarter. State Street Corp now owns 94,424 shares of the company’s stock valued at $212,000 after acquiring an additional 23,000 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Checkpoint Therapeutics by 41.2% in the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after acquiring an additional 124,787 shares in the last quarter. Virtu Financial LLC boosted its holdings in Checkpoint Therapeutics by 180.5% in the fourth quarter. Virtu Financial LLC now owns 38,157 shares of the company’s stock valued at $122,000 after purchasing an additional 24,552 shares during the period. Finally, Walleye Capital LLC acquired a new position in Checkpoint Therapeutics during the 3rd quarter worth $148,000. Institutional investors and hedge funds own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.